July 2024, Vol 14, No 7

Medical practices that prescribe drugs for their patients have an ethical and legal liability to obtain drugs that meet safety, efficacy, and quality standards. Employers have a fiduciary responsibility to their employees to provide health benefit plans that follow important US drug safety measures and help to ensure that counterfeit and/or unsafe drugs are not provided to unsuspecting employees. Yet, some specialty pharmacies and vendors are offering international drugs to employee health benefit plans. Read More ›

Various strategies to address cash flow problems in oncology practices are presented, such as tracking lapses in the revenue cycle, ensuring that the front office staff is collecting payments at the time of service whenever possible, and keeping a close eye on what has been charged on the practices credit card. Read More ›

The National Cancer Institute (NCI) Equity and Inclusion Program strives to increase the diversity of the cancer research workforce, build a more inclusive and equitable NCI community, address cancer disparities, and advance health equity. Read More ›

This new feature aims to provide ongoing lists of US-based phase 2 or 3 clinical trials that are actively recruiting, and it can be used to encourage patients to enroll in a clinical trial. This issues feature is focused on sarcoma. Read More ›

This new feature is a compendium of pioneering work by established and up-and-coming hematology oncology pharmacists and other healthcare providers working in a variety of oncology settings who published abstracts in the Journal of Hematology Oncology Pharmacy, the official publication of the Hematology/Oncology Pharmacy Association (HOPA). Read More ›

In recent years, the diagnosis of colorectal cancer (CRC) has been shifting to a younger age and a more advanced stage. This article explores risk factors for the disease and the fundamentals in managing the younger patient with CRC. Read More ›